BioMoti (London, UK), Pharmidex (London, UK) and Queen Mary University of London (London, UK) have been awarded a grant of £662,222 following the Biomedical Catalyst funding competition from Innovate UK (Swindon, UK).

The grant was awarded to support the preclinical studies of the development of novel therapeutic approaches for hard to treat tumors, including advanced ovarian, triple negative breast and pancreatic cancers. Cofunded by a further £226,769 investment from BioMoti and Pharmidex, the project focuses on Oncojan™ from BioMoti, described as a ‘sustained release precision therapeutics platform targeting CD95L mediated tumor immune evasion’. With expertise in preclinical drug development from Pharmidex and mechanisms of disease from Queen Mary University of London, the trio will investigate precision delivery of drugs to solid tumor sites and immune system activation due to CD95L targeting on tumors over the next 2 years. “It is exciting for us to be supported by Innovate UK to explore our platform’s interactions with the immune system following promising efficacy data in cancer models. BioMoti is making great progress on a final seed investment round to support commercialisation and we welcome enquiries from qualified investors,” commented Davidson Ateh (BioMoti). “We are very pleased to join BioMoti and Queen Mary University of London in the preclinical development of the Oncojan™ platform.

This Innovate UK funded project is an exciting approach to cancer therapy that could have a significant impact on patient lives,” stated Chris Ireson (Pharmidex). “We are passionate about what a difference we could make for patients, and it is great to have secured Innovate UK funding,” concluded Joanne Martin (Queen Mary University of London).

Please see the link for more information: www.biomoti.com/biomoti-pharmidex-and-queen-mary-university-of-london-secure-662222-biomedical-catalyst-award/